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Gadoliniumpohjaisia kontrastiaineita käytetään magneettikuvauksessa lisäämään kuvien kontrastia 
ja parantamaan kudosten erottelukykyä. Intravaskulaarisessa käytössä niitä on pidetty erittäin 
turvallisina ja hyvin siedettyinä, mutta viime vuosina on havaittu, että gadoliniumia voi kertyä 
aivokudokseen. Vaikka gadoliniumpohjaisten kontrastiaineiden intratekaalinen käyttö ei ole 
virallisesti hyväksyttyä, menetelmän turvallisuus on osoitettu alustavasti useissa kliinisissä 
tutkimuksissa. Mahdollisia käyttöaiheita intratekaalisella gadoliniumilla tehostetulle 
magneettikuvaukselle (GdMK) ovat muun muassa likvorivuotojen ja likvorikierron häiriöiden 
diagnostiikka. Tämän katsauksen tavoite oli selvittää GdMK:n turvallisuutta ja hyödyllisyyttä 
aivojen ja selkäydinkanavan poikkeavuuksien diagnostiikassa. 
 
Kirjallisuushaussa Medline- ja Scopus-tietokannoista etsittiin alkuperäisartikkeleita ja 
tapausselostuksia, joissa 1) arvioitiin GdMK:n turvallisuutta ja/tai hyötyä kliinisessä käytössä, ja 2) 
kuvattiin toimenpiteen suoritus yksityiskohtaisesti. Täydentävää hakua tehtiin aihetta käsittelevien 
artikkelien kirjallisuusluetteloista. Katsaukseen otettiin mukaan 28 alkuperäisartikkelia ja 8 
tapausselostusta. Neljässä tutkimuksessa GdMK:ta verrattiin suoraan yhteen tai useampaan muuhun 
kuvantamismenetelmään ja raportoitiin menetelmille diagnostisten testien tunnuslukuja (herkkyys, 
tarkkuus, PPV, NPV). Näiden neljän tutkimuksen laatua arvioitiin soveltaen QUADAS-2-
kriteereitä. Meta-analyysiä ei tehty, koska aineisto oli heterogeeninen. 
 
Yhteensä 790 tutkimushenkilöä kuvannettiin GdMK:lla. Vakavia haittatapahtumia ei raportoitu. 
Yleisin haitta oli toimenpiteen jälkeinen päänsärky, jota esiintyi 83 potilaalla (11 %). Yhdelle 
potilaalle nousi toimenpiteen jälkeen kuume, yksi kärsi ohimenevästä täydellisestä muistin-
menetyksestä (TGA) ja yksi sairastui bakteerimeningiittiin. GdMK:n herkkyys kallonpohjan 
likvorivuotojen diagnostiikassa oli 89–98 %. Kolme tutkimusta raportoi GdMK:n olevan varjoaine-
TT:tä herkempi selkäydinkanavan likvorivuotojen diagnostiikassa. Lisäksi GdMK todettiin 
hyödylliseksi araknoidaalikystien, hydrokefaluksen ja neurokystiserkoosin diagnostiikassa. 
 
Gadoliniumpohjaisten kontrastiaineiden intratekaalinen käyttö vaikuttaa olevan turvallista ja hyvin 
siedettyä. Intravaskulaariseen käyttöön liittyvät haitat tulee kuitenkin huomioida myös 
intratekaalisessa käytössä, ja gadoliniumpohjaisia kontrastiaineita tulisi käyttää varoen potilailla, 
joilla on munuaisten vajaatoiminta. Vaikka intratekaaliset annokset ovat intravaskulaarisiin 
annoksiin nähden pieniä, intratekaaliseen käyttöön voi liittyä vaikeasti ennakoitavia haittoja, sillä 
annostelureitti vaikuttaa kontrastiaineen kinetiikkaan. GdMK:n etuja ovat säteilyrasituksen 
puuttuminen ja TT:tä parempi herkkyys muun muassa likvorivuotojen diagnostiikassa, mutta 
pitkäaikaishaittojen riski on huomioitava gadoliniumin intratekaalista käyttöä harkittaessa. 
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Abstract 
 
 
Background: The intravenous use of gadolinium-based contrast agents (GBCAs) in MR imaging is 
well-established in clinical practice. GBCAs were long considered to be extremely safe, but in 
recent years some concerns have been raised over possible long-term adverse effects, including 
deposition of gadolinium in neural tissue. The intrathecal use of GBCAs is not approved by the 
EMA or FDA, but its relative safety and tolerability has been reported in several clinical studies. 
When administered intrathecally, GBCAs provide enhancement of CSF and good contrast between 
CSF and parenchyma. Therefore, potential clinical applications include evaluation of the 
subarachnoid space, CSF fistulas, and CSF flow dynamics. The objective of this review was to 
assess the safety and diagnostic value of intrathecal gadolinium-enhanced MRI (GdMRI) in clinical 
practice. 
 
Materials and methods: A search was carried out in the Medline and Scopus databases up to 30 
November 2016. Original articles and case reports that 1) evaluated the safety and/or the diagnostic 
performance of GdMRI and 2) provided detailed information on the procedure were included. Data 
was collected on study design, sample size, patient demographics, GBCA type and dose, 
administration procedure, follow-up, adverse events, and diagnostic performance. Modified 
QUADAS-2 criteria were used to assess the methodological quality of four studies that compared 
GdMRI to other imaging modalities and reported diagnostic performance characteristics for 
GdMRI. Meta-analysis was not attempted due to the heterogeneity of the included studies. 
 
Results: A total of 36 studies with 790 subjects were included. There were no reports of serious 
adverse events associated with GdMRI. The most frequent adverse effect was mild to moderate 
postprocedural headache, which was reported in 83 patients (11 %). One patient developed a fever, 
one had an episode of TGA, and one developed pneumococcal meningitis after the procedure. In 
detection and localization of skull-base CSF leaks, four studies reported a sensitivity of 89-96 % for 
GdMRI. Three studies reported improved detection and localization of spinal CSF leaks by GdMRI 
compared to CECT. The diagnostic value of GdMRI for the evaluation of arachnoid cysts, 
hydrocephalus, and neurocysticercosis was also reported in small patient series. 
 
Conclusion: The intrathecal use of GBCAs appears to be safe and well-tolerated in the short term. 
Careful consideration is called for when performing GdMRI in patients with renal insufficiency, 
and the use of high-risk compounds should be avoided in all patients regardless of renal function. 
Although intrathecal doses of GBCAs are significantly lower than intravenous doses, no direct 
comparison can be made between the two due to differences in clearance kinetics. Because the 
experience on the intrathecal use of GBCAs is limited, the long-term safety of GdMRI remains 
unclear. In the diagnosis of CSF fistulas, GdMRI appears to have a higher sensitivity than CECT, 
and several small studies have shown the potential value of GdMRI in various other clinical 
situations. The benefits of improved diagnostics and lack of radiation exposure need to be weighed 
against the potential risk of long-term adverse effects when considering the intrathecal use of 
GBCAs, especially in young patients. More research is needed on the long-term safety of GdMRI 
before its widespread clinical use can be recommended. 
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Abbreviations 
 
AS = aqueductal stenosis 
CECT = intrathecal contrast-enhanced computed tomography; (general concept including 
cisternography and myelography) 
CISS-3D = Three-dimensional constructive interference in steady state sequence in magnetic 
resonance imaging 
ETV = endoscopic third ventriculostomy 
FIESTA = fast-imaging employing steady-state acquisition sequence in magnetic resonance 
imaging 
GBCA = gadolinium-based contrast agent 
Gd-BOPTA = gadobenic acid 
Gd-DTPA = gadopentetate dimeglumine 
GdMRI = intrathecal gadolinium-enhanced magnetic resonance imaging; contrast agent injected via 
lumbar puncture; (general concept including cisternography and myelography) 
GdMRV = intrathecal gadolinium-enhanced magnetic resonance ventriculography; contrast agent 
injected via ventricular puncture 
HRCT = high-resolution computed tomography 
NCC = neurocysticercosis 
NPH = normal pressure hydrocephalus 
NSF = nephrogenic systemic fibrosis 
PC-MRI = phase-contrast magnetic resonance imaging 
RC = radionuclide cisternography 
SIH = spontaneous intracranial hypotension 
STV = spontaneous third ventriculostomy 
T2MRI = unenhanced T2-weighted magnetic resonance imaging 
VPS = ventriculoperitoneal shunting 
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1 Background 
 
1.1 Gadolinium-based contrast agents in magnetic resonance imaging  
 
Gadolinium-based contrast agents (GBCAs) are used in magnetic resonance imaging (MRI) to 
facilitate the detection of disease, e.g. inflammation, infection, and tumors. In GBCAs, gadolinium 
is attached to a chelating agent to prevent toxicity.1 GBCAs generate a positive image contrast in 
T1-weighted sequences by shortening the T1 relaxation time of the hydrogen protons of nearby 
water molecules.2 GBCAs were approved for intravenous use in 1988, and by the early 2000s their 
use had become routine in clinical practice.3 In intravenous use, GBCAs have been considered to be 
well tolerated and safe as they rarely cause allergic or other adverse reactions. The incidence of 
acute hypersensitivity reactions occurring within 24 hours of administration ranges from 0.004 % to 
0.7 %, with the majority categorized as minor or moderate. The incidence of severe reactions is 
0.001–0.01 %, which is approximately one third of the frequency associated with the use of 
iodinated contrast agents.4 
While considered safe in the short term, concerns have been raised over long-term adverse effects 
of GBCAs, foremost the risk of nephrogenic systemic fibrosis (NSF). NSF is a rare but potentially 
lethal fibrosing disorder that primarily affects the skin but may also involve other organs, including 
lung, heart, and kidney.5, 6 The first cases of NSF were reported in the late 1990s, and the 
connection between NSF and the use of GBCAs was confirmed in 2006. The risk of NSF correlates 
with the total cumulative dose of GBCAs and delayed elimination of the contrast agent due to renal 
impairment. After the discovery of the causal relationship between GBCAs and NSF, restrictions 
were placed on the use of GBCAs in patients with impaired renal function, and the incidence of 
NSF has since decreased significantly.7 
Another potential cause for concern is the deposition of gadolinium in brain and bone tissue 
following intravenous administration of GBCAs. In the early 2000s, traces of gadolinium were 
discovered in the bone of patients undergoing hip arthroplasty three to eight days after receiving 
GBCAs intravenously.8 Accumulation of residual gadolinium in the brain was first suspected in 
2014, when areas of hyperintensity were seen on unenhanced T1-weighted sequences of patients 
with multiple previous intravenous gadolinium-enhanced MRI examinations.9 Shortly thereafter, 
McDonald et al. reported gadolinium deposition in the brain of patients who had previously 
received GBCAs. Unlike NSF, accumulation of gadolinium seems to also occur in patients with 
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normal renal function. As no studies have been conducted on medical conditions occurring after 
recurrent GBCA exposure, the clinical significance of gadolinium deposition remains unclear.1 
According to several studies, some GBCAs are associated with a higher risk of NSF, and it appears 
that the same compounds are more likely to accumulate in neural tissue.7 GBCAs may be classified 
regarding the risk of NSF in several ways. The European Medicines Agency (EMA) has based its 
classification on the molecular structure of the compounds.10 In this system, GBCAs with a 
macrocyclic structure are considered safer, because they are more stable than linear compounds and 
thus less likely to dissociate and cause toxic damage.1 Another system, created by The American 
College of Radiology (ACR), is based on confirmed cases of NSF that have been linked to a 
specific GBCA in relation to an estimate of administered doses. In both systems, the linear GBCAs 
gadodiamide and Gd-DTPA are assigned to the group of compounds with a high risk, and 
restrictions on their use in patients with renal impairment are recommended.10 Since the risk of NSF 
correlates with impaired renal function, it has also been suggested that the route of elimination of 
GBCAs may affect the risk related to their use. However, as the only GBCA compound that has 
significant biliary elimination is currently only indicated for MRI of the liver, this theory is of 
limited value in clinical practice.7 
According to recent guidelines by the European Society of Urogenital Radiology, the use of high-
risk GBCAs is contraindicated in patients with severe renal impairment (GFR < 30 ml/min/1.73 m2) 
and should be avoided in patients with moderate renal impairment (GFR < 60 ml/min/1.73 m2). In 
cases of high-grade renal dysfunction (GFR < 15 ml/min/1.73 m2), only low-risk GBCAs may be 
used and only on vital indication. In all cases and regardless of the compound used, GBCAs should 
be administered in the lowest dose possible for sufficient diagnostic imaging.10 
 
1.2 Intrathecal use of gadolinium-based contrast agents 
 
The neurotoxic potential of GBCAs in intrathecal use was demonstrated in animal models in the 
1980s and the 1990s. In rat experiments, the medial lethal dose of Gd-DTPA was reported to be    
50 µmol/g brain, and signs of toxicity (e.g. myoclonus, ataxia) were seen at doses of 5 µmol/g brain 
and higher.11 In one study, histologic examination of the brain and spinal cord of rats after 
intraventricular Gd-DTPA injection showed loss of oligodendroglia, hypertrophy of astrocytes, and 
destruction of myelin sheaths.11 The severity of the neuropathologic changes was dose-related, with 
first signs of toxic damage seen at 5 µmol/g brain. Some regions of the CNS (e.g. the superior 
olivary nuclei and the spinal cord) were affected more frequently than others, although the 
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distribution of the lesions was variable.11 The same group of researchers carried out a similar study 
using gadodiamide instead of Gd-DTPA, and found differences in the localization and character of 
the CNS lesions. The lesions produced by gadodiamide were mostly located in the cerebellum, and 
unlike with Gd-DTPA, no lesions were seen in the brain stem nuclei or the spinal cord. No 
morphologic changes or signs of toxicity were seen below a dose of 1.25 µmol/g brain of 
gadodiamide.12  
The intrathecal use of GBCAs in humans was first reported in 1997, when a Gd-DTPA-enhanced 
MR ventriculography (GdMRV) was performed on two patients with leptomeningeal 
carcinomatosis in order to assess the patency and function of intraventricular catheter systems.13 In 
1999, the safety and imaging characteristics of Gd-DTPA-enhanced MR myelography were 
evaluated in a pilot study of 11 patients by Zeng et al.14 At doses of 0.2–1 mL (equal to 0.07–0.36 
µmol/g brain) diluted with 5 mL of CSF, they reported no neurologic alterations or other adverse 
effects immediately after the procedure or during a follow-up of 9 to 15 months, but delayed scans 
obtained at 4 to 30 hours after administration of Gd-DTPA showed enhancement of the brain 
parenchyma. High signal intensity of CSF was seen on T1-weighted sequences at all doses. After 
these preliminary reports, several prospective studies on the subject have been conducted, but the 
intrathecal use of GBCAs has not been approved by the EMA or FDA and remains an off-label 
use.1, 15, 16 
While low doses of intrathecal GBCAs seem to be well tolerated, there are reports of serious 
adverse events after accidental high-dose injection of GBCAs into the subarachnoid space. Li et 
al.17 reported a case of a 34-year-old woman who underwent myelography for brachial plexus injury 
and was inadvertently administered 15 mL of Gd-DTPA (equivalent to 5.35 µmol/g brain), up to  
30 times the recommended dose, via lumbar puncture. The immediate adverse reactions included 
headache and vomiting, and 1 hour after the injection the patient became comatose and suffered 
episodic systemic seizures. Cerebral edema and accumulation of Gd-DTPA in the brain parenchyma 
was seen in MRI, and MR angiography showed vasospasm of major cerebral arteries. The patient 
was treated with methylprednisolone, chlorpromazine, promethazine, and naloxone, and eventually 
made a full recovery. Enhancement of the brain parenchyma was still evident in MRI 8 months after 
the incident. 
Samardzic et al.18 reported a case of gadolinium-induced encephalopathy in a 67-year-old woman 
who was inadvertently injected with 4 mL of gadodiamide (equivalent to 1.4 µmol/g brain) via 
lumbar puncture during an epidural steroid injection. Three hours after the procedure, the patient 
developed nausea, dyspnea, and disorientation. MRI showed progressive enhancement of the brain 
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parenchyma and EEG showed signs of encephalopathy. The patient received dexamethasone and 
was discharged two days later in good condition. 
Park et al.19 described a case of 42-year-old man who received 6 mL of Gd-DTPA (equivalent to 
2.16 µmol/g brain) intrathecally instead of the intended iodine-based contrast agent. Six hours later, 
the patient developed confusion, global aphasia, vomiting, focal seizures, and severe rigidity. The 
patient’s CT scan showed diffuse high density, but no specific abnormalities were seen in digital 
subtraction angiography (DSA). The patient received anticonvulsants and intravenous hydration. In 
four days his condition improved, and the high-density signal was no longer seen in CT. When all 
symptoms had subsided, the patient was discharged. 
 
1.3 Target conditions 
 
1.3.1    Cerebrospinal fluid rhinorrhea and otorrhea 
 
Cerebrospinal fluid rhinorrhea or otorrhea refers to the leakage of CSF into the sinonasal cavities or 
the middle ear cavity and mastoid cells, respectively. The leakage results from a skull base bony 
defect, or multiple defects, accompanied by a dural tear or tears. The patients present with leakage 
of clear fluid from the nose or the ear, or, in some cases, recurring bacterial meningitis as a 
complication of an untreated CSF leak. In CSF otorrhea, the clinical presentation depends on 
whether the tympanic membrane is intact; CSF leakage from the ear occurs only if the tympanic 
membrane is perforated. When the tympanic membrane is intact, CSF leaks via the Eustachian tube 
and otorrhea presents as a nasal leak.20, 21 
Most skull base CSF leaks are either posttraumatic (80 %) or iatrogenic (16 %) in origin, while only 
4 % occur spontaneously.21 Posttraumatic CSF leaks carry a higher risk of meningitis than 
iatrogenic or spontaneous leaks but are also more likely to resolve without treatment. In 
posttraumatic leaks, a delayed onset of the leak, failure to respond to conservative treatment, and a 
history of meningitis are considered indications for surgical repair.22 Surgical intervention is also 
recommended in spontaneous leaks due to the low probability of resolution without treatment.21 
Differential diagnosis of skull base CSF leaks includes allergic rhinitis, nasal polyps, and chronic 
sinusitis. When a CSF leak is suspected, the fluid may be tested for β2-transferrin, a protein only 
found in CSF and perilymph, to determine its origin. If the fluid tests positive for β2-transferrin, 
imaging studies are needed to localize the leak site. CSF leak repair is almost exclusively performed 
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via endoscopy, and imaging studies are imperative for preoperative planning. A combination or 
HRCT and intrathecal contrast-enhanced CT (CECT) has been widely used in the detection of skull 
base CSF leaks. HRCT facilitates surgical planning by providing an excellent view of paranasal 
anatomy, but relies on indirect signs of leakage, e.g. bony defects, fracture lines, erosions, 
pneumocephalus, or fluid levels in the paranasal sinuses. In cases with multiple bony defects, the 
identification of the exact leak site may not be possible by HRCT alone. In CETC, the use of 
iodinated contrast agent allows direct visualization of the leak, but its ability to detect low-flow 
leaks or hairlike communications is limited and therefore its sensitivity is low. Heavily T2-weighted 
non-contrast enhanced MRI (T2MRI) may allow direct visualization of the leak, but the 
hyperintense CSF may be difficult to differentiate from mucosal inflammation in the sinuses, and 
high rates of false positives have been reported.20, 21 
 
1.3.2 Spontaneous intracranial hypotension 
 
Spontaneous intracranial hypotension (SIH) is a disorder characterized by signs and symptoms 
associated with low CSF pressure, most commonly postural headache. While the exact 
pathophysiology of SIH is not known, the low CSF pressure is thought to result from slow CSF 
leaks via dural defects in the spinal area, typically at the nerve root sleeves of the cervicothoracic 
junction or the thoracic spine. It is unclear why some individuals develop non-traumatic CSF leaks, 
but Marfan syndrome, meningeal diverticulae, and other connective tissue abnormalities have been 
suggested as predisposing factors.23, 24 
The patients present with postural headache which occurs or worsens while standing upright and 
subsides in a supine position, usually within 15 to 30 minutes after lying down.23 Other signs and 
symptoms may include nausea, meningism, hypacusis, tinnitus, or cognitive disturbances.23 The 
headaches associated with low CSF pressure are considered to result from intracranial venous 
dilatation, which may cause meningeal traction, subdural effusions, or subdural hematomas due to 
the rupture of bridging veins.24 
SIH is diagnosed based on symptoms, typical findings in clinical tests (e.g. low CSF opening 
pressure during lumbar puncture), and imaging. Cranial MRI findings in SIH may include 
downward sagging of the brain, diffuse pachymeningeal enhancement, engorged venous structures, 
and subdural fluid collections. However, SIH cannot be excluded based on a normal finding in 
MRI.23 
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The first line of treatment in SIH is conservative, i.e. bed rest, oral caffeine and hydration. When 
conservative treatment fails, one or several blind blood patches may be performed. If the symptoms 
prevail after blind blood patches, measures that require localization of the leak site, such as targeted 
blood patching or surgical repair of the dura, may be considered.23 Imaging modalities for localizing 
the leak site include CECT and radionuclide cisternography (RC).25 While indirect signs indicating 
spinal CSF leakage may be seen in RC, its ability to localize the leak is limited by its poor spatial 
resolution and lack of cross-sectional images.26, 27 CECT is considered to be the most sensitive 
technique for detection of spinal CSF leaks, but as it involves considerable exposure to ionizing 
radiation (> 10 mSv), there is a need for an alternative imaging technique.25 
 
1.3.3 Arachnoid cysts 
 
Arachnoid cysts are benign fluid collections within the arachnoid membranes typically diagnosed in 
children and adolescents. Most patients with arachnoid cysts are asymptomatic and do not require 
further examinations or treatment. However, cysts may obstruct CSF flow or compress neural 
structures, leading to nonspecific or localized symptoms or hydrocephalus.28 In symptomatic 
patients, surgical intervention may be considered. Since cranial surgery involves considerable risk, 
appropriate patient selection is important. It has been suggested that patients with cysts that do not 
communicate with the surrounding CSF space are more likely to benefit from surgery than patients 
with communicating cysts. Therefore, determining the fluid dynamics of the cysts via imaging 
studies may be helpful in patient selection. CECT and RC have been used for this purpose, but in 
pediatric patients, radiation exposure is a concern.28 Non-enhanced MRI sequences such as three-
dimensional constructive interference in steady state (CISS-3D) or phase-contrast MRI (PC-MRI) 
have been proposed as alternative techniques, but CISS-3D only provides morphologic information 
and in PC-MRI complex CSF flow patterns may lead to false positives.29 
 
1.3.4 Neurocysticercosis 
 
Neurocysticercosis (NCC) is an infectious disease caused by the helminth Taenia solium. Although 
rare in first world countries, it is a leading cause of acquired epilepsy in tropical low-income 
countries.30 In NCC, vesicles or cysts containing larva may be seen in the brain or spinal cord 
parenchyma, the subarachnoid space, or the ventricles. Eventually the cysts degenerate and calcify. 
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Depending on the location, number, and size of the lesions, patients present with a range of 
neurological symptoms and signs, including epileptic seizures. In extraparenchymal forms of NCC, 
the cysts may obstruct CSF flow, leading to hydrocephalus and intracranial hypertension.30 
The diagnostic work-up of NCC includes neuroradiological imaging, CSF analysis, and blood tests 
for antibodies. In extraparenchymal NCC, the cysts may be difficult to detect in CT scans because 
the cyst membrane is thin and the cyst fluid isodense with CSF. MRI is more sensitive than CT in 
detecting viable cysts, but calcified lesions are better seen on CT. The use of intrathecal contrast 
may help to ascertain the presence of cysticerci and avoid unnecessary antiparasitic therapy in 
patients without active disease.30,31 
 
1.3.5 Hydrocephalus 
 
In hydrocephalus, obstruction of CSF flow leads to excessive accumulation of CSF and dilatation of 
the cerebral ventricles. It may or may not be associated with increased intracranial pressure. In 
obstructive (non-communicating) hydrocephalus, CSF flow is obstructed proximal to the apertures 
of the fourth ventricle, typically due to a tumor, a cyst, or postinflammatory arachnoid adhesions.32 
The most common site of obstruction is the cerebral aqueduct.33 In communicating hydrocephalus, 
the obstruction is distal to the apertures of the fourth ventricle, e.g. in the arachnoid granulations or 
in the basal cisterns. Communicating hydrocephalus is often secondary to meningitis, subarachnoid 
hemorrhage, or cranial trauma.32 
Normal pressure hydrocephalus (NPH) is a type of communicating hydrocephalus seen in elderly 
patients. It is characterized by a typical triad of symptoms: dementia, urinary incontinence, and gait 
ataxia.34 While there is no consensus on the pathophysiology of NPH, impaired re-absorption of 
CSF by arachnoid granulations has been considered a contributing factor.35 Imaging examinations 
are useful in differentiating between NPH and other causes of dementia, e.g. Alzheimer’s disease 
and vascular dementia. Typical MRI findings in NPH include ventriculomegaly, narrowed sulci, 
and deep white matter ischemia.36, 37 In RC, radioactive contrast material seen in the ventricles for 
more than 24 hours after intrathecal administration is considered indicative of NPH.38 CSF 
diversion by shunting leads to clinical improvement in some but not all patients, and thus far 
predicting which patients will benefit from the procedure has been difficult, although it has been 
suggested that patients with a history of meningitis or subarachnoid hemorrhage may respond better 
than patients with idiopathic NPH.32 
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In obstructive hydrocephalus, typical MRI findings include dilatation of the lateral and third 
ventricles, and bulging of the floor of the third ventricle. The patency of the cerebral aqueduct may 
be assessed with conventional T2MRI, in which a hypointense signal extending into the third and 
fourth ventricles (flow-void signal) is considered a sign of a patent aqueduct.37 Treatment options 
for obstructive hydrocephalus include ventriculoperitoneal shunting (VPS) and endoscopic third 
ventriculostomy (ETV).37 In ETV, a small opening is made in the floor of the third ventricle, 
allowing CSF to bypass the obstruction by flowing directly into the basal cisterns. In the case of a 
spontaneous third ventriculostomy (STV), which is sometimes seen in obstructive hydrocephalus, 
surgical treatment is considered unnecessary as it is unlikely to provide further benefit. The 
presence of an STV may be assessed by CISS-3D, which provides detailed anatomical information 
of the third ventricle, or PC-MRI, which allows assessment of CSF flow.36 
Multiloculated hydrocephalus refers to the presence of isolated fluid-filled compartments within the 
ventricles. The formation of septae results from a disruption of the ependymal lining and often 
arises following intraventricular hemorrhage or meningitis. The septae may obstruct CSF flow and 
cause symptoms by mass effect. Imaging studies are needed for evaluating possible benefits of 
operative treatment, as patients with communicating intraventricular compartments are considered 
less likely to benefit from a procedure.39 
 
 
2 Case report 
 
A 33-year-old man presented with symptoms of intracranial hypotension, including postural headache and 
dizziness, but conventional MRI of the brain did not demonstrate typical findings for SIH. After 
conventional spinal MRI, conventional myelography, and CT myelography, GdMRI was performed with    
0.4 mL of Gd-DTPA mixed with 4 mL of saline. A spinal drain was used for intrathecal contrast 
administration, and T1-weighted sequences were obtained before and 5 minutes after administration of      
Gd-DTPA. A fluid collection anterior to the medulla was seen in all imaging studies and enhancement of the 
fluid collection was seen with intrathecal contrast. However, no fluid compartment was found on surgical 
exploration. It was concluded that the fluid collection is located subdurally and communicates with the 
subarachnoid space. While GdMRI did not provide additional information in this case, it proved feasible and 
useful in situations where repeated imaging of the entire spine is required, with the advantage of no radiation 
exposure. Case and images courtesy of Jussi Numminen, HUS Radiology. 
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Figure 1. T2-weighted MRI (upper left); CT myelography (upper right); unenhanced T1-weighted MRI 
(lower left); T1-weighted MRI with intrathecal Gd-DTPA (lower right). The fluid collection is not apparent 
in sagittal images. 
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Figure 2. T1-weighted MRI with intrathecal Gd-DTPA (left); fast-imaging employing steady-state 
acquisition (FIESTA) MRI (right). Fluid exhibiting high signal intensity is seen anterior to the medulla. 
   
 
 
3 Materials and methods 
 
For this review, a search was carried out in the Medline and Scopus databases up to 30 November 
2016. The search strategies for the two databases are described in Appendix 1. The citation lists of 
relevant articles, including reviews, were searched by hand for additional references. Original 
articles and case studies that 1) evaluated the safety and/or diagnostic performance of GdMRI, and 
2) provided detailed information on the procedure were included in this review. The search was 
limited to English language articles available in full text via Tampere University Library. 
The abstracts and titles of 51 studies were screened and full text articles of 23 potentially relevant 
studies were retrieved and assessed for eligibility by the author. An additional 13 eligible studies 
were identified by searching the citation lists of relevant articles. A summary of the study selection 
process is shown in Appendix 2. 
The following data was extracted from full text articles: year of publication, sample size, patient 
demographics, target condition, imaging techniques, reference standard test, diagnostic performance 
characteristics, follow-up, and adverse events. 
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Four studies compared GdMRI to other imaging techniques and reported diagnostic performance 
characteristics (sensitivity, specificity, PPV, and/or NPV) for GdMRI. For these studies, the 
applicability and risk of bias were assessed based on modified QUADAS-2 criteria. 
Due to the heterogeneity of the studies included in this review, statistical analysis was not 
attempted. 
 
 
4 Results 
 
4.1 Basic characteristics of included studies 
 
Thirty-six studies (28 original articles and 8 case reports) met the inclusion criteria and were 
included in this review. The objective of the included studies was to evaluate the safety and/or 
diagnostic value of GdMRI. A total of 790 subjects (756 patients and 34 controls) were assessed. In 
the original articles, the sample size ranged from 5 to 95 patients, with a mean of 26 patients. The 
mean age of patients was available for 15 studies, with an average of 38 years (range 1 month to 85 
years). Ten studies included pediatric patients (age 16 or younger), and in two of these all subjects 
were children. Out of eight case reports, two included pediatric patients. The proportion of men 
ranged from 33 % to 87 %. Out of 790 subjects, 437 were male and 353 female. (Table 1.) 
All subjects underwent at least one GdMRI examination. Four studies included controls and in three 
of these, the controls also underwent GdMRI and were included in the analysis.36, 40, 41 Controls who 
underwent GdMRI were suspected with intracranial abnormalities other than the target condition. In 
most studies, both immediate and delayed imaging was performed. Delayed images were obtained 
up to 96 hours after the administration of GBCAs. Imaging findings were evaluated by one to three 
experienced neuroradiologists. The reported follow-up ranged from an observation period of 24 
hours to annual evaluations for up to six years, with an estimated average of 12 months. 
GBCAs were administered via lumbar puncture in 29 studies. Gd-DTPA (with a concentration of 
0.5 mmol/mL) was used in 25 of these studies with a total of 663 subjects (629 patients and 34 
controls), with doses ranging from 0.2 to 1 mL, equal to 0.07–0.36 µmol/g brain. Gadodiamide    
(0.5 mmol/mL) was used in three studies with a total of 33 patients in doses of 1–2 mL, equal to 
0.36–0.72 µmol/g brain. Gadobutrol (1 mmol/mL) was used in one study of 26 patients with a dose 
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of 1 mL, equal to 0.72 µmol/g brain. The use of Gd-BOPTA (0.5 mmol/mL) was reported in two 
patients with doses of 0.3 mL and 1 mL, equal to 0.11 and 0.36 µmol/g brain, respectively. In three 
studies GBCAs were injected simultaneously with an iodine-based contrast agent (iohexol or 
iomeprol).24, 42, 43 In one study, 0.5–1 mL of iotrolan 240 was injected prior to the injection of Gd-
DTPA to control needle placement.44 (Table 2). 
In three studies and two case reports with a total of 39 patients, GBCAs were administered directly 
into the ventricles via ventricular puncture. In two other studies, GBCAs were administered to some 
patients via lumbar puncture and some via ventricular puncture, transfontanelle ventriculostomy 
(TF), or ventriculoperitoneal shunt reservoir (VPS). Gd-DTPA was used in four studies, with doses 
ranging from 0.01 mmol to 1 mmol, equal to 0.0072–0.72 µmol/g brain. Gadodiamide was used in 
three studies, with doses of 0.02–0.5 mmol, equal to 0.014–0.036 µmol/g brain. (Table 2.) 
 
4.2 Adverse events 
 
There were no reports of gadolinium toxicity immediately after the procedure or during follow-up. 
One pediatric patient developed a fever after the administration of 1 mL of Gd-DTPA; the fever 
resolved with antihistamines and was attributed to a hypersensitivity reaction to the contrast agent.45 
There were no other reports of immediate or delayed hypersensitivity reactions. One patient with a 
suspected skull base CSF leak developed meningitis caused by Streptococcus pneumoniae 12 hours 
after the administration of Gd-DTPA via lumbar puncture,46 and one patient who was being 
examined for SIH had an episode of transient global amnesia (TGA) after the administration of 
gadobutrol via lumbar puncture.24 Apart from these two cases, no significant adverse events were 
reported. 
Mild or moderate post-procedural headache was reported in 13 studies, with an incidence of                
8–36 %. The headache resolved in all cases with conservative treatment (e.g. mild analgesics and/or 
bed rest) within 24–72 hours. In one study of 95 patients, nausea was reported in six patients and 
vomiting in two.47 The symptoms resolved with bed rest within 24 hours. Adverse events are 
reported in Table 2. 
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Table 1. Basic characteristics of included studies. 
 Year of 
publication 
Type of study No. patients;       
controls 
Male, female Age in years  
(mean, range) 
Target condition 
Wenzel et al. 2000 Case report 4 1, 3 26–62 CSF rhinorrhea 
Jinkins et al.  2002 Prospective 15 8, 7 9–68 CSF rhinorrhea 
Reiche et al. 2002  10 7, 3 42 CSF rhinorrhea 
Aydin et al. 2004 Prospective 20 12, 8 19–56 CSF rhinorrhea 
Arbeláez et al. 2007  24 15, 9 37, 7–61 CSF rhinorrhea 
Goel et al. 2007 Prospective 10 5, 5 13–52 CSF rhinorrhea 
Aydin et al. 2008 Prospective 51 32, 19 36, 19–61 CSF rhinorrhea 
Algin et al. 2010 Prospective 17 13, 4 32, 11–70 CSF rhinorrhea 
Selcuk et al. 2010  85 45, 40 15–72 CSF rhinorrhea 
Vanopdenbosch et al. 2011 Prospective 27 9, 18 45, 18–73 CSF rhinorrhea, SIH 
Ecin et al. 2013  60 33, 27 37, 18–70 CSF rhinorrhea 
Mehdi et al. 2014 Case report 1 0, 1 9 mo CSF rhinorrhea 
Ragheb et al. 2014  24 16, 8 33–62 CSF rhinorrhea 
Kraemer et al. 2005 Case report 1 0, 1 19 SIH 
Albayram et al. 2007 Case report 1 0, 1 32 SIH 
Albayram et al. 2008  19 7, 12 40, 25–77 SIH 
Akbar et al. 2012 Retrospective 41 14, 27 61, 22–80 SIH 
Albes et al. 2012 Prospective 26 15, 11 21–72 SIH 
Chazen et al. 2014 Retrospective 24 14, 10 51, 20–85 SIH 
Sharma et al. 1999 Case report 1 1, 0 60 Neurocysticercosis 
Higuera-Calleja et al. 2015 Prospective 14 8, 6 32–64 Neurocysticercosis 
Tali et al. 2004 Prospective 20 12, 8 37, 5–67 Arachnoid cysts 
Tan et al. 2015  23 20, 3 0.3–9.7 Arachnoid cysts 
Singh et al. 2008 Prospective 12 9, 3 12, (2 mo–50 y) Hydrocephalus, ETV 
Algin et al. 2010 Prospective 25; 9 14, 11; 4, 5 23, 1–67 Hydrocephalus, AS 
Algin et al. 2011 Prospective 36; 15 14, 22; 9, 6 63, 46–75 NPH 
Algin et al. 2011 Prospective 11; 10 8, 3; 6, 4 17, 2–35 Hydrocephalus, STV 
Gandhoke et al. 2013  18 11, 7 2–14 mo Multiloculated hydrocephalus 
Zeng et al. 1999 Prospective 11 9, 2 40, 23–66 Various 
Tali et al. 2002 Prospective 95 50, 45 1 mo–78  Various 
Joseph et al. 2003  5 2, 3 6 mo–49 Various 
Munoz et al. 2007  10 8, 2 1 mo–16 Various 
Siebner et al. 1997 Case report 2 0, 2 60, 52 Drug device patency 
Kraemer et al. 2002 Case report 1 0, 1 58 Spinal cyst 
Hattingen et al. 2009 Retrospective 8 3, 5 27–73 CSF leakage 
Munoz et al. 2014 Case report 4 2, 2 4–17 Craniophraryngiomas 
AS = aqueductal stenosis; ETV = endoscopic third ventriculostomy; NPH = normal pressure hydrocephalus; STV = spontaneous third ventriculostomy;  
SIH = spontaneous intracranial hypotension
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Table 2. Adverse events and administration technique. 
 Type of GBCA No. patients 
+ controls 
Dose (mL) Dilution Administration 
procedure 
Follow-up 
(mean, range) 
Adverse events 
(headache, other) 
Siebner et al. Gd-DTPA 2 0.01 mmol Saline VP NA - 
Zeng et al. Gd-DTPA 11 0.2, 0.5, 1 CSF LP 9–15 mo - 
Wenzel et al. Gd-DTPA 4 1 Saline LP NA - 
Jinkins et al. Gd-DTPA 15 0.5 CSF LP 6–12 mo 20 % 
Reiche et al. Gd-DTPA 10 11 Saline LP 0–2 y - 
Tali et al. Gd-DTPA 95 0.5–1 CSF LP 6–12 mo 20%, nausea (6 pt), 
vomiting (2 pt) 
Albayram et al. Gd-DTPA 1 0.5 Saline LP 12 mo - 
Aydin et al. Gd-DTPA 20 0.5 - LP 1 mo, 3 mo 20 % 
Tali et al. Gd-DTPA 20  CSF LP 6 mo 27 % 
Arbeláez et al. Gd-DTPA 24 1 - LP 0–9 mo 36 % 
Munoz et al. Gd-DTPA 10 0.8–2 CSF LP, VPS, TF 48 h 20 % 
Albayram et al. Gd-DTPA 19 0.5 Saline LP 12 mo 26 % 
Aydin et al. Gd-DTPA 51 0.5 - LP 4.1 y, 3–6 y 24 % 
Hattingen et al. Gd-DTPA 8 0.5 CSF LP 24 h NA 
Algin et al. Gd-DTPA 25 + 9 0.5–1 - LP NA NA 
Algin et al. Gd-DTPA 17 1 - LP 24 h 30 %, fever (1 pt) 
Selcuk et al. Gd-DTPA 85 0.5 Saline LP 38.6 mo 8 % 
Algin et al. Gd-DTPA 36 + 15 1 - LP 72 h 27 % 
Algin et al. Gd-DTPA 11 + 10 0.5–1 - LP NA NA 
Vanopdenbosch et al. Gd-DTPA 27 0.5 - LP NA meningitis (1 pt) 
Akbar et al. Gd-DTPA 41 0.5 Saline LP 24 h–6.8 y 2 % 
Ecin et al. Gd-DTPA 60 0.5–1 - LP 24 h 10 % 
Chazen et al. Gd-DTPA 24 0.32 - LP NA - 
Munoz et al. Gd-DTPA 4 0.1–0.2 Saline, CSF VP NA - 
Mehdi et al. Gd-DTPA 1 0.5 Saline LP 6 mo - 
Ragheb et al. Gd-DTPA 24 0.5 - LP NA 25 % 
Tan et al. Gd-DTPA 23 0.5 CSF LP, VP 1–10 mo 4 % 
Sharma et al. Gadodiamide 1 0.5 - LP NA - 
Joseph et al. Gadodiamide 5 0.02–0.04 mmol   CSF VP 9–15 mo - 
Goel et al. Gadodiamide 10 2.03 - LP 1–12 mo 10 % 
Singh et al. Gadodiamide 12 1 CSF VP 0–14 mo - 
Gandhoke et al. Gadodiamide 18 0.02–0.04 mmol - VP 10 mo, 3 mo–2 y - 
Higuera-Calleja et al. Gadodiamide 14 1 - LP 18 mo, 12–24 mo - 
Kraemer et al. Gd-BOPTA 1 1 - LP NA - 
Kraemer et al. Gd-BOPTA 1 0.3 Saline LP 4 mo - 
Albes et al. gadobutrol 26 14 - LP NA TGA (1 pt) 
1 with 0.5–1.0 mL iotrolan; 2 with 10 mL iohexol; 3 with 5 mL iohexol; 4 with 9 mL iomeprol; NA = not available; LP = lumbar puncture; VP = ventricular puncture
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4.3 Clinical applications 
 
4.3.1 CSF rhinorrhea and otorrhea 
 
In 10 original articles and two case reports, the main objective was the detection and localization of 
a CSF leak in patients with clinically suspected CSF rhinorrhea or otorrhea. One additional study 
included patients suspected with either CSF rhinorrhea or SIH. A total of 334 patients were assessed 
for CSF rhinorrhea. Excluding case reports, the sample size ranged from 10 to 85 patients, with a 
mean of 32 patients. The mean age was available in five studies, with an average of 37 years (range 
9 to 72 years). One study and one case report included pediatric patients (children under the age of 
16). Gender distribution was available for all but one study with two target conditions, in which the 
gender distribution for each patient group was not reported. In the remaining 12 studies, the 
proportion of men ranged from 50 % to 76 %. Of 321 patients, 187 were male and 134 female. 
Beta2-transferrin testing was performed in some or all patients as part of the clinical evaluation in 
five studies.22, 45, 48, 49, 50 
Direct comparisons between imaging modalities were made in four studies. Out of these four, 
surgical or endoscopic findings were used as a reference standard in three studies,42, 45, 51 while in 
one study,48 β2-transferrin testing was also accepted as a reference standard. In one study,45 only 
eight out of ten positive findings were confirmed surgically. The range for sensitivity and 
specificity of GdMRI in the detection of CSF rhinorrhea was 89–96 % and 80–100 %, respectively. 
Methodological evaluation of the four studies is described in Table 3. 
Ragheb et al.51 compared GdMRI with HRCT in a series of 24 patients. Sensitivity, specificity, 
PPV, and NPV for GdMRI were 96 %, 100 %, 100 %, and 50 %, respectively, and for HRCT, 65 
%, 33 %, 88 %, and 11 %, respectively. Ecin et al.48 compared GdMRI with unenhanced T2-
weighted MRI (T2MRI) in a series of 60 patients. Sensitivity, specificity, PPV, and NPV calculated 
for GdMRI were 92 %, 80 %, 76 %, and 93 %, respectively, and for T2MRI, 56 %, 77 %, 64 %, and 
71 %, respectively. Goel et al.42 described a series of 10 consecutive patients, nine of whom 
underwent GdMRI, CECT, and CISS-3D, while one patient only underwent GdMRI. Sensitivity 
and specificity for GdMRI were 89 % and 100 %, respectively; for CISS-3D, 75 % and 100 %, 
respectively; and for CECT, 37.5 % and 100 %, respectively. Algin et al.45 compared GdMRI to 
CISS-3D and HRCT in a series of 17 patients. Beta2-transferrin testing was carried out in eight 
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Table 3. Diagnostic performance characteristics of imaging modalities in detection of skull base CSF leaks in 
surgically confirmed groups. 
 Modalities Sensitivity Specificity Accuracy 
Goel et al.  GdMRI 89 % 100 % 100 % 
 CISS-3D 75 % 100 % 100 % 
 CECT 38 % 100 % 100 % 
Algin et al.  GdMRI 100 % - - 
 HRCT 88 % - - 
 CISS-3D 76 % - - 
Ecin et al.  GdMRI 92 % 80 % - 
 T2MRI 56 % 77 % - 
Ragheb et al.  GdMRI 96 % 100 % 96 % 
 HRCT 65 % 33 % 61 % 
GdMRI = intrathecal gadolinium-enhanced MRI 
CISS-3D = Three-dimensional constructive interference in steady state  
CECT = intrathecal contrast-enhanced computed tomography 
HRCT = high-resolution computed tomography   
T2MRI = unenhanced T2-weighted MRI  
 
 
Table 4. Methodological assessment by modified QUADAS-2 criteria. 
 Goel et al. Algin et al. Ecin et al. Ragheb et al. 
Consecutive or random patient sample Yes Yes Unclear Unclear 
Selection criteria clearly described No No Yes Yes 
All patients received the same reference standard test No No No Yes 
Patients received the same reference standard test 
regardless of index test results 
No No Yes Yes 
Index test results interpreted without knowledge of 
results of the reference standard 
No No Yes Yes 
Reference standard results interpreted without 
knowledge of results of the index test 
No No No Unclear 
Criteria for a positive imaging result defined clearly Yes Yes No No 
 
 
patients. Ten patients had a positive GdMRI, and leaks were confirmed surgically in eight of these 
patients. The same eight patients were tested for β2-transferrin and all eight tested positive. 
Sensitivity for GdMRI, HRCT, and CISS-3D were 100 %, 88 %, and 76 %, respectively. Specificity 
was not calculated due to the lack of a reliable reference standard. Diagnostic performance 
characteristics are reported in Table 3. 
In the remaining seven studies, no direct comparison between modalities was made. However, in 
two of these studies all patients underwent both HRCT and GdMRI. 49, 52 A total of 105 patients 
were assessed, and GdMRI found a leak in 80 patients, 78 of which were confirmed surgically (one 
patient refused surgery and one was referred to another hospital). HRCT showed bony defects in all 
patients. The patients with a negative GdMRI were followed conservatively for 3 to 12 months and 
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did not require surgical treatment during follow-up. No false negative or false positive findings in 
GdMRI were reported.  
In five studies, no other imaging modalities besides GdMRI were used. A total of 113 patients were 
evaluated. GdMRI showed a leak in 92 patients, 77 of which were confirmed surgically. The 
remaining 15 patients with a positive GdMRI were followed conservatively, and their symptoms 
resolved during follow-up. One patient with a negative GdMRI had a history of recurring bacterial 
meningitis and was therefore also referred for surgery, which revealed a leak in the ethmoidal 
region (false negative). Reasons for refraining from surgery in patients with a positive GdMRI 
included low-flow fistulas or intermittent leakage.44, 46, 50, 52, 53 
The two case reports described a 9-month-old child with CSF otorhinorrhea and four adults with 
CSF rhinorrhea. GdMRI was performed due to inconclusive findings in previous imaging studies or 
surgical exploration. In all patients, the leak site was successfully localized by GdMRI.54, 55 
 
4.3.2 Spontaneous intracranial hypotension 
 
In five original articles and two case reports, patients with clinically suspected SIH underwent 
GdMRI for the detection and localization of spinal CSF leaks. In one additional study, 14 out of 27 
patients underwent GdMRI due to suspected SIH, while the remaining 13 patients were suspected 
with skull base CSF leaks. A total of 136 patients were evaluated. In the study with two target 
conditions, the gender distribution for patients suspected with SIH was not available. Of the 
remaining 112 patients, 51 were male and 61 female. The patients’ age range was 19–85 years, with 
an estimated average of 40 years. Two of the studies were retrospective. In three studies, the 
patients underwent both CECT and GdMRI, and in one study, GdMRI was the only imaging 
modality used. Imaging findings were not confirmed surgically, and no reference standard for 
detection of spinal CSF leaks was defined.25, 43, 46, 56, 57, 58, 59, 60  
Albayram et al.56 reported a series of 19 consecutive patients with suspected SIH, who did not 
undergo other imaging in addition to GdMRI. Of these 19 patients, 17 were found to be positive for 
a CSF leak on GdMRI, and the leak was successfully localized in 14 cases. The remaining three 
patients showed diffuse leakage due to a high-volume fistula. The writers suggest GdMRI for 
patients in whom blind epidural blood patches fail to sufficiently alleviate symptoms. 
Albes et al.24 reported a series of 26 patients with clinically suspected SIH. Twenty-three patients 
underwent both CECT and GdMRI, while three patients only underwent GdMRI. Leaks were 
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detected in all patients at the cervical, thoracic, and/or lumbar spine. GdMRI identified at least one 
leak site in 10 patients with no leaks detected in CECT. The writers concluded that GdMRI is more 
sensitive than CECT in detecting spinal CSF leaks, especially leaks associated with meningeal 
diverticula. 
Chazen et al.43 conducted a retrospective study of 24 patients, who underwent both CECT and 
GdMRI. CECT detected a leak in three patients, while GdMRI identified a leak in nine. All three 
leaks seen in CECT were also identified by GdMRI. Of the six cases where a leak was only seen in 
GdMRI, four were related to meningeal diverticula. The writers concluded that GdMRI is more 
sensitive than CECT in the diagnosis of spinal CSF leaks. 
A retrospective study by Akbar et al.58 looked at patients who underwent GdMRI after at least one 
prior CECT examination. Out of 41 patients, 24 had a negative finding in CECT and were 
considered the target population of the study. GdMRI detected a leak in five patients with a 
previous negative CECT, and the site of the leak was identified in four out of five cases. Out of 17 
patients with a positive finding in prior CECT, GdMRI detected a leak in 12 cases but only 
identified the leak site in five cases. These cases were typically complex, with persisting symptoms 
despite multiple previous interventions. The writers concluded that GdMRI is useful in patients 
with a strong clinical suspicion of SIH and a negative finding in previous CECT, but in patients 
with a positive CECT, GdMRI is of limited value. 
In a retrospective study by Hattingen et al.,59 eight patients with suspected spinal CSF leaks 
underwent GdMRI, while six controls underwent unenhanced T1-weighted MRI with a frequency-
selective fat saturation pulse (SPIR). In all subjects, a hyperintense signal imitating a CSF leak was 
seen at the apex of the lungs. The writers concluded that the described artefact may lead to false 
positives for spinal leaks. 
In a study by Vanopdenbosch et al.,46 13 patients with suspected SIH underwent GdMRI. Leaks 
were detected in nine patients, eight of which were repaired surgically. Although no comparison to 
other imaging modalities was made, the writers suggest that GdMRI is more sensitive than CECT in 
detecting spinal CSF leaks. 
Two case reports described one patient with Marfan syndrome and one patient with Behcet’s 
disease. The patients presented with symptoms of SIH and underwent GdMRI after other imaging 
modalities failed to localize dural leaks. Multiple dural defects were revealed by GdMRI in both 
patients.57, 60 
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4.3.3 Arachnoid cysts 
 
In a series of 23 pediatric patients (age range 3 months to 9.7 years) reported by Tan et al., GdMRI 
was performed to evaluate communication between arachnoid cysts and surrounding CSF spaces. 
The cysts were classified as complete communicating, incomplete communicating, or non-
communicating based on the enhancement pattern seen in GdMRI. The patients were randomized 
into two groups: in one group, all patients underwent surgery regardless of the GdMRI findings      
(n = 10); in the other group, only patients with non-communicating or incomplete communicating 
cysts were operated on (n = 5) and patients with communicating cysts were followed conservatively 
(n = 8). Although there was no significant difference in the clinical outcome or cyst shrinkage 
between the two groups, the writers concluded that GdMRI may be of use in treatment planning for 
patients with arachnoid cysts, as surgery may be unnecessary in patients with communicating cysts. 
In a study by Tali et al, 20 patients with a mean age of 37 years (age range 5–67 years) underwent 
GdMRI. All patients had been diagnosed with arachnoid cysts based on previous CT or MR 
imaging. Cyst enhancement was evaluated in both immediate and delayed post-contrast imaging, 
with delayed imaging carried out 24 hours after the injection of contrast media. Immediate 
enhancement of the cyst fluid was seen in nine patients, and delayed enhancement was seen in 
another six patients. In the remaining five patients, no enhancement of the cyst fluid was 
demonstrated. Of these five, symptomatic patients (n = 3) were referred for surgery, while clinical 
and imaging follow-up was planned for asymptomatic patients (n = 2). Of the patients with 
communicating cysts, three underwent surgery because their symptoms were believed to result from 
regional mass effect caused by the cysts. Clinical improvement was seen in all patients who 
underwent surgery. In the patients who were not treated surgically, no change was seen in follow-up 
at 6 months. The writers concluded that GdMRI may be useful in patient selection for arachnoid 
cyst surgery. 
 
4.3.4 Neurocysticercosis 
 
In a study by Higuera-Calleja et al.,31 14 patients (8 males, 6 females; age range 32–64) with 
suspected neurocysticercosis underwent GdMRI. In the patients’ prior CT examinations, no cysts or 
vesicles had been seen, but one patient had a finding suggestive of a cysticercus vesicle in a 
previous MRI examination. GdMRI showed vesicles or cysts in 10 patients in the basal 
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subarachnoid space, the lateral ventricle, the fourth ventricle, or the spinal canal. In four patients, no 
vesicles or cysts were detected. The writers concluded that GdMRI is useful in the detection of 
cystic lesions, especially ones located in the basal cisterns, spinal subarachnoid space and 
ventricles. 
Sharma et al.61 reported the case of a 60-year-old man presenting with seizures, ataxia, dementia, 
and urinary incontinence. The patient’s CT scans showed mild ventricular dilatation, focal dilatation 
of sulci, and calcified lesions in the brain parenchyma, but no cysticercal cysts or vesicles. MRI 
exams showed cysticercal cysts in the parenchyma and strands resembling a cobweb in the dilated 
sulci. GdMRI confirmed the presence of cisternal cysticerci, which were clearly demonstrated as 
filling defects in the cisternal spaces. The patient was diagnosed with intraparenchymal and 
cisternal cysticercosis. 
 
4.3.5 Hydrocephalus 
 
In a study by Singh et al.,61 intrathecal gadolinium-enhanced MR ventriculography (GdMRV) was 
performed in 10 patients with communicating hydrocephalus to evaluate the success of an ETV 
procedure. In preoperative GdMRV, flow of contrast media beyond the fourth ventricle was seen in 
all patients. Postoperative GdMRV showed immediate flow of contrast media into the prepontine 
and basal cisterns in seven patients, and ETV was considered successful in these cases. No 
symptoms indicating failure or closure of ETV were seen during a follow-up time of 7 to 14 
months. In three patients, ETV was considered unsuccessful as there was no flow of contrast seen in 
the prepontine cistern postoperatively and symptoms of raised ICP persisted after the procedure. 
The writers concluded that GdMRV was useful in determining the patency of ETV and the 
subarachnoid space. 
Algin et al.41 compared GdMRI, PC-MRI, and CISS-3D in the evaluation of the presence of STV in 
patients with obstructive hydrocephalus. Eleven patients and 10 controls underwent GdMRI, PC-
MRI, and CISS-3D. STV was seen in six patients in PC-MRI, three patients in CISS-3D, and two 
patients in GdMRI. GdMRI was considered as the reference standard, and surgical treatment was 
offered to the eight patients with no STV seen in GdMRI. Two of these patients refused surgery, 
and the remaining six underwent VPS, cyst fenestration, or ETV. Surgical findings were consistent 
with imaging findings, and the surgically treated patients improved clinically after surgery. The 
writers concluded that due to their noninvasive nature, PC-MRI and CISS-3D should be considered 
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primary examinations for the evaluation of the presence of STV, and positive findings should be 
verified by GdMRI. 
In another paper by the same group,40 PC-MRI and CISS-3D were compared to GdMRI in the 
evaluation of aqueductal stenosis. Aqueductal patency was evaluated in 25 patients with suspected 
AS and nine controls by GdMRI, PC-MRI, and CISS-3D. GdMRI was considered as a reference 
standard, but imaging findings were not confirmed surgically. In eight patients, PC-MRI or CISS-
3D showed partial flow while GdMRI showed complete obstruction or normal flow. The writers 
suggest that if partial narrowing of the aqueduct is suspected based on PC-MRI and CISS-3D, 
GdMRI should be performed to verify the presence of AS. 
Gandhoke et al.39 performed GdMRV in 18 pediatric patients (age range 2–14 months) with 
suspected multiloculated hydrocephalus to evaluate the presence of ventricular septae and 
obstruction of CSF flow. GdMRV verified the diagnosis of multiloculated hydrocephalus in 17 
patients and excluded it in one patient. Four cases showed free flow of CSF within the ventricular 
system, leading to simplification of the planned surgical procedure. In 13 cases, multiple isolated 
compartments were seen in the ventricles, and endoscopic treatment was planned accordingly. 
Postoperative GdMRV was obtained in eight patients. Findings included a closed or non-
functioning ETV in four patients and the successful fenestration of septae in four patients. During a 
follow-up of 3 months to 2 years, 9 out of 13 endoscopically treated patients remained shunt free. 
The writers concluded that GdMRV is complementary to CISS-3D in the assessment of 
multiloculated hydrocephalus and may reduce the number of unnecessary procedures. 
Algin et al.38 performed GdMRI in 36 patients with suspected NPH and 15 controls in order to 
assess whether imaging findings predict response to shunt surgery. The presence of contrast 
material in the lateral ventricles was assessed at 12, 24 and 48 hours after the injection of Gd-
DTPA. The presence of contrast material in the lateral ventricles at 24 and 48 hours after the 
injection was significantly more prevalent in the patient group than in the control group, but it did 
not correlate with response to shunt treatment. The sensitivity and specificity for GdMRI in 
predicting response to shunt surgery were 100 % and 17 %, respectively. 
Joseph et al.63 described a series of five nonconsecutive patients presenting with symptoms of 
hydrocephalus. GdMRV was performed in all five to evaluate obstruction of CSF flow or the 
patency of third ventriculostomy. The writers concluded that GdMRV is useful in the evaluation of 
CSF dynamics. 
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4.3.6 Other 
 
In three studies, patients were enrolled based on various symptoms and signs for which cranial or 
spinal imaging with intrathecal contrast was requested. A total of 116 patients were assessed. The 
purpose of these studies was to evaluate the safety and imaging characteristics of GdMRI. In a pilot 
study by Zeng et al.,14 11 adult patients presenting with symptoms of the lower extremities or lower 
back underwent GdMRI. The largest series of patients was reported by Tali et al.,47 who performed 
GdMRI in 95 patients (50 males, 45 females; age range 1 month to 78 years). Imaging indications 
included paraparesis, subcutaneous paraspinal mass, and suspected cranial or spinal CSF leaks. 
Muñoz et al.64 performed GdMRI in 10 pediatric patients (age range 1 month to 16 years) with 
various suspected intracranial abnormalities, in whom previous standard MRI provided insufficient 
information for diagnosis or treatment planning. In all three studies, there were no reports of severe 
adverse events. Tali et al. reported postprocedural headache in 19 patients, nausea in six, and 
episodes of vomiting in two. All symptoms resolved within 24 hours with bed rest. Imaging 
findings included spinal cysts, intraventricular and intraparenchymal cysts, spinal stenosis, 
intervertebral disc herniation, meningomyelocele, and arachnoiditis.  It was concluded that GdMRI 
is a relatively safe and feasible procedure with potential clinical applications in assessment of CSF-
filled spaces and CSF flow. 
In the first report of intrathecal use of GBCAs, Siebner et al.13 performed GdMRV in two patients 
with leptomeningeal carcinomatosis to evaluate the function of intraventricular drug devices. Both 
patients tolerated the procedure well, and good contrast between CSF and brain parenchyma was 
achieved. The writers concluded that GdMRI may be valuable in imaging of CSF-related disorders. 
One case report described the use of intracystic GdMRI in the evaluation of residual giant-cystic 
craniopharyngiomas in four pediatric patients (age range 4 to 17 years). GdMRI was performed to 
rule out communication between the intracystic space and the surrounding structures before 
intracystic therapy. In three cases, no communication was seen, and in one case, GdMRI showed 
leakage of contrast material from the cyst despite a previous negative finding in contrast-enhanced 
CT cystography. The writers concluded that GdMRI is superior to contrast-enhanced CT in the 
evaluation of cyst leakage.65 
Kraemer et al.66 performed GdMRI with 1 mL of Gd-BOPTA in a 58-year old female patient with a 
spinal cyst. Sedimentation of the contrast material was seen in the lumbosacral subarachnoid space. 
The writers suggested that a lower concentration of contrast agent be used and mixed with a small 
volume of CSF before administration to avoid sedimentation. 
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5 Discussion 
 
For this paper, 28 original articles and 8 case reports were reviewed, with a total of 790 subjects 
undergoing at least one GdMRI examination. The most frequently used GBCA was Gd-DTPA, 
which was administered to 663 patients in 29 studies. The other GBCAs used were gadodiamide, 
gadobutrol, and Gd-BOPTA. Gd-DTPA was most commonly administered at a dose of 0.5 mL 
(equal to 0.17 µmol/g brain), which was sufficient to achieve excellent contrast between CSF and 
brain or spinal cord parenchyma. 
The neurotoxicity of GBCAs has been established in animal models, and there are several reports of 
neurotoxic effects in humans following accidental high-dose injection of GBCAs. In the studies 
included in this review, GBCAs were used at diagnostic doses and no signs or neurotoxicity were 
reported. There were no reports of allergy or hypersensitivity to GBCAs apart from one case of 
fever that was attributed to a hypersensitivity reaction to the contrast agent (Gd-DTPA). One patient 
with CSF rhinorrhea developed pneumococcal meningitis 12 hours after the intrathecal 
administration of Gd-DTPA, but this was likely a complication of a CSF leak and not the 
procedure. Also, one patient had an episode of TGA after the intrathecal administration of 
gadobutrol, but it remains unclear whether the procedure caused or contributed to the event. Mild to 
moderate postprocedural headache was reported in 13 studies, with an incidence ranging from 8 to 
36 %. The headache resolved in all patients with conservative treatment within 24–72 hours and 
should be attributed to lumbar puncture and not GBCAs. Higher rates of postprocedural headache 
have been reported in patients after CECT examinations, most likely because the high viscosity of 
iodine-based contrast agents requires the use of larger diameter needles.26 
For the time being, it is unclear whether intrathecal administration of GBCAs has any long-term 
adverse effects. Even though such effects have not been reported thus far, the risk of long-term 
neurotoxicity cannot be excluded, as the procedure has been performed in a fairly small number of 
patients and mostly in studies conducted 10 years ago or less. The longest reported mean follow-up 
in a study was 4.12 years and as seen with intravenous use of GBCAs and NSF, it may take 
considerably longer for an adverse effect to manifest and be recognized as such. It should be 
presumed that the risk of NSF and gadolinium deposition is inherent in both intravenous and 
intrathecal use of GBCAs. Although the doses of GBCAs in intrathecal use are significantly lower 
than intravenous doses (e.g. a total dose of 0.25 mmol and 0.1–0.2 mmol/kg for Gd-DTPA, 
respectively), no direct comparison can be made between the two because the kinetics of clearance 
of contrast agents differ depending on the route of administration. However, since both the risk of 
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NSF and gadolinium deposition seem to correlate with the total cumulative dose of GBCAs 
administered, the risk associated with a single dose of intrathecal GBCAs should be small. 
The reported clinical applications of GdMRI included detection and localization of CSF leaks, 
assessment of obstructions of CSF flow, demonstration of cysts, and evaluation of communication 
between cysts and surrounding structures. In the studies reviewed for this paper, GdMRI was most 
frequently used to assess patients with suspected CSF rhinorrhea or otorrhea. Compared to CECT, 
GdMRI was found to have a higher sensitivity and specificity in detection and localization of skull 
base CSF leaks. This has been attributed to improved detection of low-flow leaks and hairlike CSF 
fistulas by GdMRI.42 Iodinated contrast agents have a higher viscosity than GBCAs and are thus 
less likely to flow past narrow bony and dural defects, which may lead to false negatives. Also, 
contrast between CSF and bone is poor in CECT as both appear hyperdense, whereas GdMRI 
provides good contrast between hypointense bone and hyperintense CSF. Fat-saturated sequences 
are recommended for suppressing the signal intensity of bone marrow.42 
A recent review on diagnostic imaging of CSF rhinorrhea suggests HRCT as the primary imaging 
modality in all patients with suspected skull base CSF leaks.20 HRCT provides a detailed view of 
the bony structures and is considered necessary for surgical planning. In cases where a single bony 
defect is seen in HRCT, no further imaging may be needed. If multiple defects are identified or if 
the clinical presentation does not match the findings in HRCT, fat-suppressed T2MRI may be 
recommended as a second-line imaging modality due to its noninvasive nature. T2MRI has a high 
sensitivity, but the hyperintense CSF may be difficult to differentiate from mucosal inflammation in 
the sinuses, and high rates of false positives have been reported.42, 44 In cases where HRCT and 
T2MRI fail to provide sufficient information for surgical planning, GdMRI may be recommended. 
Surgical findings were used as a reference standard for diagnosing CSF rhinorrhea in most of the 
studies, but apart from one study, patients with a negative finding in GdMRI were not referred for 
surgery or endoscopy, so the negative results were not confirmed. However, the patients with a 
negative GdMRI were followed conservatively and their symptoms were relieved during follow-up. 
This suggests that GdMRI correctly identified the patients who did not require surgery, either 
because they did not have a CSF leak or because the leak resolved spontaneously. In three studies, 
the selection criteria included a minimum duration of symptoms (range 2 weeks to 3 months). Since 
the probability of spontaneous cessation of a posttraumatic CSF leak is fairly high during the first 
weeks, it seems appropriate to require a minimum duration of symptoms in order to avoid 
unnecessary invasive imaging procedures. Also, a β2-transferrin test should be performed in all 
patients to differentiate a CSF leak from other causes of nasal discharge. 
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In patients with suspected spinal CSF leaks, GdMRI was considered superior to CECT in showing 
diffuse or low-flow leaks and in detecting meningeal diverticula. The longer imaging half-life of 
GBCAs as compared to iodine-based contrast agents enables delayed imaging and better 
visualization of slow, low-flow leaks.43, 56 The improved detection of diffuse leaks by GdMRI was 
attributed to the lower viscosity of GBCAs.56 CECT was considered superior to GdMRI in the 
localization of high-flow leaks due to the shorter acquisition time of CECT.43 Two out of three 
studies that compared GdMRI to CECT found GdMRI to be more sensitive in the detection and 
localization of spinal CSF leaks. 
The primary imaging examination in patients with suspected SIH is cranial MRI.23 In patients who 
remain symptomatic despite conservative treatment and blind epidural blood patches, the leak site 
should be localized so that a targeted blood patch or surgical repair of the dural tear may be 
performed. Since CECT involves considerable exposure to ionizing radiation and does not appear to 
be safer or more sensitive than GdMRI, the latter may be suggested as a primary imaging procedure 
for localization of spinal CSF leaks. 
In the assessment of patients with suspected obstructive hydrocephalus, GdMRI was compared to 
PC-MRI and CISS-3D in two studies by the same group.40, 41 Due to their noninvasive nature,     
PC-MRI and CISS-3D may be considered primary imaging modalities in patients with suspected 
aqueductal stenosis or spontaneous third ventriculostomy, while GdMRI may be recommended in 
cases where the results of PC-MRI and CISS-3D are inconclusive. GdMRI was also considered 
useful in the evaluation of endoscopic third ventriculostomy patency.62 In patients with suspected 
normal pressure hydrocephalus, GdMRI failed to predict response to shunt surgery, whereas CECT 
has previously been shown to predict surgical outcome.38, 63 In children with multiloculated 
hydrocephalus, preoperative GdMRI reduced the number of unnecessary procedures and was 
deemed useful.39 
GdMRI was also found to be useful in the evaluation of arachnoid cysts, and although it was not 
compared to other imaging methods, it may be a viable alternative to CECT due to radiation 
concerns, especially since most patients are children or adolescents.28, 29 In patients with suspected 
neurocysticercosis, GdMRI improved the detection of cysticerci in the cisternal spaces, ventricles, 
and spinal subarachnoid space.31, 61 
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6 Conclusion 
 
The intrathecal administration of GBCAs appears to be a relatively safe and well-tolerated 
procedure in the short term. As with intravenous use, careful consideration is called for when 
administering intrathecal GBCAs to patients with renal insufficiency, and the use of high-risk 
compounds should be avoided in all patients regardless of renal function. Although intrathecal 
doses of GBCAs are significantly lower than doses in intravenous use, no direct comparison can be 
made between the two regarding possible long-term risks, because the kinetics of clearance differ 
depending on the route of administration. There is limited experience of the intrathecal use of 
GBCAs and it may therefore involve risks that have yet to be recognized. GdMRI appears to be 
more sensitive than CECT in the detection and localization of cranial and spinal CSF leaks, and 
several small studies have reported the diagnostic value of GdMRI in various other clinical 
situations. The benefits of improved diagnostics and lack of radiation exposure need to be weighed 
against the risk of long-term adverse effects when considering intrathecal administration of GBCAs, 
especially in young patients. More research is needed on the long-term safety of the intrathecal use 
of GBCAs and the diagnostic value of GdMRI in different clinical situations. 
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Appendix 1. Search strategies. 
 
Database(s): Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) 
Daily, Ovid MEDLINE and Versions(R)   
# Searches Results 
1 Gadolinium DTPA/ or Gadolinium/ 19730 
2 Magnetic Resonance Imaging/ 336136 
3 intrathecal gado*.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier, synonyms] 
45 
4 Injections, Spinal/ 11856 
5 3 or 4 11880 
6 1 and 2 and 5 43 
7 limit 6 to (english language and humans) 34 
 
Database: Scopus 
( TITLE-ABS-KEY ( "intrathecal gado*" )  AND  TITLE-ABS-KEY ( mri ) )   
 
 
Appendix 2. Study selection process. 
 
 
